Gilead Maintains Confidence in PrEP Franchise as U.S. Preventive Services Task Force Faces Uncertainty
SHERIDAN, WYOMING – August 10, 2025 – Gilead Sciences is signaling strong confidence in its HIV prevention portfolio, including the twice-yearly injectable PrEP therapy Yeztugo, despite growing uncertainty over the future of the U.S. Preventive Services Task Force (USPSTF). The federally recognized panel’s recommendations currently mandate insurance coverage for preventive services, but a postponed meeting has fueled speculation that Health Secretary RFK Jr. could overhaul or dismantle the group.
Regulatory Shifts Could Reshape PrEP Access
The USPSTF plays a critical role in defining access to preventive medicines by issuing recommendations that directly influence payer coverage. For HIV prevention, its endorsement has helped accelerate adoption of both oral and long-acting injectable PrEP solutions. A structural change to the task force could: